Latest research on Lantus

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.

Lantus interactions

Physicians would order insulin glargine (Lantus) vials and insulin Aspart (NovoLog) flexpens without specifying doses. [source, 2015]
Patient was started on Quinine 648 mg and Doxycycline 100 mg, intravenous (IV) fluids, Lantus 21 U, Lispro 7 U, and was monitored in telemetry unit of medicine (Figures 1–3). [source, 2015]
The patient's current drug prescriptions include Lantus 10 U/day, Apidra 6 U #3/day, and Nutriflex lipid peri [+ Humulin-R (regular insulin) 15 U] every other day (EOD), and chemotherapy was paused due to general weakness. [source, 2015]
Stimulations included: insulin neutral protamine Hagedorn (NPH) (Insuman Basal, Sanofi Aventis, Paris, France), insulin glargine (Lantus, Sanofi Aventis), first metabolite of glargine (M1, Sanofi Aventis), second metabolite of glargine (M2, Sanofi Aventis), glulisine (Apidra, Sanofi Aventis), lispro (Humalog, Eli Lilly, Indianapolis, IN, USA), insulin X10 (not marketed, Novo Nordisk, Bagsvaerd, Denmark), Aspart (B28Asp, Novo Nordisk), detemir (Levemir, Novo Nordisk) and insulin-like growth factor 1 (IGF1) (Increlex, Ipsen, Basking Ridge, NJ, USA). [source, 2015]
4 days before admission his endocrinologist stopped his Lantus (insulin glargine) and prescribed him on canagliflozin 100 mg oral daily along with Glyburide and Metformin. [source, 2015]
T1D treatment involved the recombinant human insulin, NPH (67%); regular insulin (33%); synthetic rapid-acting insulin, NovoRapid (52%); and others: Humalog, Lantus, Levemir and Apidra (~10%). [source, 2015]
The treatments included: insulin NPH (Insuman Basal, Sanofi Aventis, Gouda, The Netherlands), insulin glargine (Lantus, Sanofi Aventis), insulin X10 (AspB10, Novo Nordisk, Alphen aan den Rijn, The Netherlands) and IGF1 (Increlex, Ipsen, Hoofddorp, The Netherlands). [source, 2015]
For the last 20 years, he had required Humulin R three times daily (11 IU/at morning, noon, and evening), and Lantus once a day (22 IU/at midnight). [source, 2015]
Patients continued baseline treatment with Metformin (1-2 gm in divided doses) and MDI insulin (either premixed human 70/30 insulin twice daily or basal-bolus regimen with basal insulin glargine [rDNA origin; Lantus, Sanofi, Paris, France] and insulin Aspart [rDNA origin; Novolog, Novo Nordisk, Bagsvaerd, Denmark] at each meal). [source, 2015]
One patient was prescribed insulin Glargine (Lantus, Sanofi-Aventis), one patient was prescribed insulin Aspart (NovoLog, Novo Nordisk), and one patient did not report taking any medication for diabetes. [source, 2015]